Tower Research Capital LLC (Trc) Immunovant, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $3.68 Billion
- Q3 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Immunovant, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 1,016 shares of IMVT stock, worth $27,950. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,016
Previous 14,142
92.82%
Holding current value
$27,950
Previous $373,000
92.76%
% of portfolio
0.0%
Previous 0.01%
Shares
18 transactions
Others Institutions Holding IMVT
# of Institutions
212Shares Held
66.9MCall Options Held
2.3MPut Options Held
631K-
Vanguard Group Inc Valley Forge, PA6.66MShares$183 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.92MShares$135 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.35MShares$120 Million4.41% of portfolio
-
Armistice Capital, LLC New York, NY3.55MShares$97.6 Million1.62% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.33MShares$91.6 Million0.06% of portfolio
About Immunovant, Inc.
- Ticker IMVT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 129,077,000
- Market Cap $3.55B
- Description
- Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...